Latest Nitazoxanide Stories
Global Phase 3 Clinical Trial to Study NT-300 for Treatment of Acute Uncomplicated Influenza TAMPA, Fla., April 18, 2013 /PRNewswire/ -- Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The Phase 3 clinical trial has been initiated in the United States, will continue in Australia and New...
$44 Million Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300 TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract...
People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library. Hepatitis C affects around 170 million people worldwide. In some cases, infection leads to chronic liver disease, liver failure or liver cancer,...
April Flowers for redOrbit.com - Your Universe Online Researchers at Weill Cornell Medical College have found that an off-patent anti-inflammatory drug that costs about two cents for a daily dose can also kill both replicating and non-replicating drug-resistant tuberculosis in the laboratory. Few currently approved TB drugs can do this, and resistance to those is spreading. Reported in the Proceedings of the National Academy of Sciences, the study points to a potential new therapy for...
TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The clinical trial enrolled 624 patients at 74 outpatient primary care centers...
TAMPA, Fla., Nov. 1, 2010 /PRNewswire/ -- Romark Laboratories announced that data from studies of nitazoxanide in hepatitis C are being presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting® in Boston, October 30 - November 2, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) "The data presented at AASLD provide...
TAMPA, Fla., Oct. 21 /PRNewswire/ -- Romark Laboratories, L.C. and Intercell AG (VSE; "ICLL") today announced plans to commence clinical trials of Romark's antiviral drug, nitazoxanide, in combination with Intercell's investigational therapeutic hepatitis C virus (HCV) vaccine, IC41, during the first half of 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) Intercell's vaccine candidate has demonstrated a...
VIENNA, Oct. 21 /PRNewswire/ -- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011. Intercell's vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral...
TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 in New Orleans, Louisiana. (Logo:...
TAMPA, Fla., April 15 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress(TM) 2010, the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. (Logo:...
